CARGO Therapeutics
CRGX

$18.85

1.87%

Market Cap: $865M

About: Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Employees: 150

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]

94% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 16

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

12% more funds holding

Funds holding: 65 [Q1] → 73 (+8) [Q2]

2.59% more ownership

Funds ownership: 92.54% [Q1] → 95.13% (+2.59%) [Q2]

12% less capital invested

Capital invested by funds: $813M [Q1] → $716M (-$96.4M) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$28

49%

upside

Avg. target

$33

75%

upside

High target

$37

96%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Robert Burns 39% 1-year accuracy 56 / 143 met price target	75%upside $33	Buy Reiterated	13 Aug 2024
Piper Sandler Biren Amin 57% 1-year accuracy 8 / 14 met price target	80%upside $34	Overweight Maintained	13 Aug 2024
HC Wainwright & Co. Robert Burns 39% 1-year accuracy 56 / 143 met price target	75%upside $33	Buy Initiated	22 Jul 2024
Chardan Capital Geulah Livshits 11% 1-year accuracy 2 / 19 met price target	49%upside $28	Buy Initiated	8 Jul 2024
Piper Sandler Biren Amin 57% 1-year accuracy 8 / 14 met price target	96%upside $37	Overweight Initiated	27 Jun 2024

See Analyst Rankings

Financial journalist opinion

The Motley Fool

Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week

The cancer-focused biotech published its second-quarter results. Its loss was much narrower than analysts had expected.

Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week

CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.

CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now

Many investors steer clear of limelight stocks. These ideas might already be overvalued and often aren't the breakout stocks that can deliver significant returns.

Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now

CARGO Therapeutics to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences.

CARGO Therapeutics to Participate in Upcoming Investor Conferences

CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing

– Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $110.0 million, before deducting placement agent fees and other expenses.

CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing

Zacks Investment Research

What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock

CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock

Zacks Investment Research

Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?

The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel 1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – – Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) –

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

See News Rankings